Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.46 EUR
Change Today +0.02 / 4.59%
Volume 0.0
UXI1 On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 3:08 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (UXI1) Snapshot

Open
€0.44
Previous Close
€0.44
Day High
€0.46
Day Low
€0.43
52 Week High
10/28/14 - €2.78
52 Week Low
08/27/15 - €0.43
Market Cap
15.8M
Average Volume 10 Days
250.0
EPS TTM
--
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (UXI1)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (UXI1) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (UXI1) Details

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/31/15
Founded in 1992

cyclacel pharmaceuticals inc (UXI1) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $530.6K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $324.4K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

cyclacel pharmaceuticals inc (UXI1) Key Developments

Cyclacel Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Cyclacel Pharmaceuticals, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. The company's net loss applicable to common shareholders for the second quarter ended June 30, 2015 was $3.4 million, or $0.10 per basic and diluted share, compared to a net loss income applicable to common shareholders of $4.9 million, or $0.22 per basic and diluted share for the second quarter ended June 30, 2014. Revenue for the three months ended June 30, 2015, was $0.3 million compared to $0.4 million for the same period of the previous year. The revenue is related to grants from the European Union and the Biomedical Catalyst of the United Kingdom government. Operating loss was $5,575,000 against $3,617,000 a year ago. Loss from continuing operations before taxes was $5,635,000 against $3,752,000 a year ago. Net loss from continuing operations was $4,819,000 or $0.22 per basic and diluted share against $3,347,000 or $0.10 per basic and diluted share a year ago. For the six months, the company reported total revenue of $752,000 against $808,000 a year ago. Operating loss was $10,985,000 against $8,915,000 a year ago. Loss from continuing operations before taxes was $11,081,000 against $9,427,000 a year ago. Net loss from continuing operations was $9,696,000 or $0.47 per basic and diluted share against $8,259,000 or $0.28 per basic and diluted share a year ago. Net loss applicable to common shareholders was $9,781,000 or $0.46 per basic and diluted share against $8,359,000 or $0.28 per basic and diluted share a year ago.

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Cyclacel Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 11, 2015

Cyclacel Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Cyclacel Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UXI1:GR €0.46 EUR +0.02

UXI1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for UXI1.
View Industry Companies
 

Industry Analysis

UXI1

Industry Average

Valuation UXI1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.